Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 144.84% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 15.56 Bn | - | -6.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.27% |
| Dec 31, 2025 | -26.03% |
| Sep 30, 2025 | -11.02% |
| Jun 30, 2025 | 15.79% |
| Mar 31, 2025 | -8.39% |
| Dec 31, 2024 | 10.78% |
| Sep 30, 2024 | -19.23% |
| Jun 30, 2024 | -35.08% |
| Mar 31, 2024 | -40.83% |
| Dec 31, 2023 | 16.33% |
| Sep 30, 2023 | -19.42% |
| Jun 30, 2023 | -20.43% |
| Mar 31, 2023 | -28.57% |
| Dec 31, 2022 | 2.80% |
| Sep 30, 2022 | -55.65% |
| Jun 30, 2022 | -53.05% |
| Mar 31, 2022 | -56.14% |
| Dec 31, 2021 | -8.58% |
| Sep 30, 2021 | -94.89% |
| Jun 30, 2021 | -109.09% |